Becton, Dickinson and Company (BDX)
| Market Cap | 48.44B -10.3% |
| Revenue (ttm) | 22.48B +18.5% |
| Net Income | 942.00M -40.6% |
| EPS | 3.33 -39.2% |
| Shares Out | 272.39M |
| PE Ratio | 30.54 |
| Forward PE | 13.43 |
| Dividend | $4.20 (2.38%) |
| Ex-Dividend Date | Sep 9, 2026 |
| Volume | 287,684 |
| Open | 177.60 |
| Previous Close | 176.42 |
| Day's Range | 175.66 - 178.30 |
| 52-Week Range | 140.11 - 213.08 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 195.67 (+10.97%) |
| Earnings Date | Aug 6, 2026 |
About BDX
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, va... [Read more]
Financial Performance
In fiscal year 2025, BDX's revenue was $21.84 billion, an increase of 8.24% compared to the previous year's $20.18 billion. Earnings were $1.68 billion, a decrease of -1.58%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for BDX stock is "Buy." The 12-month stock price target is $195.67, which is an increase of 10.97% from the latest price.
News
Becton, Dickinson and Company Transcript: Wells Fargo 21st Annual Healthcare Conference
Management highlighted strong growth from focused platforms, ongoing margin expansion, and disciplined pricing. Key headwinds from Alaris, vaccines, and China are expected to ease, while innovation and capital allocation remain priorities. More strategic details and new product updates will be shared at the December Analyst Day.
3 Dividend Stocks From a Value Pro
In a rocky market, dividend stocks with generous yields and solid growth prospects may be just what your portfolio needs—if you can find them.
Becton Dickinson price target raised to $200 from $185 at BofA
BofA analyst Travis Steed raised the firm’s price target on Becton Dickinson (BDX) to $200 from $185 and keeps a Neutral rating on the shares after having hosted investors at…
Becton Dickinson announces STANCE clinical trial enrollment milestone
Becton Dickinson (BDX) announced a milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE Scaffold in breast revision surg...
BD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical Innovation
STANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contr...
BD to Present at Wells Fargo 21st Annual Healthcare Conference
FRANKLIN LAKES, N.J., Aug. 26, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo...
Becton Dickinson names Gary Sorsher as Chief Quality Officer
Becton Dickinson (BDX) announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8. Most recently, he served as chief quality officer at Edward...
BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire
FRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Gary Sorsher has been named execut...
Becton Dickinson completes enrollment in PREVENT trial
Becton Dickinson (BDX) announced the completion of enrollment in the PREVENT clinical trial evaluating Phasix Mesh for the prevention of incisional hernias. Following completion of the primary endpoin...
Becton Dickinson price target raised to $208 from $204 at Citi
Citi raised the firm’s price target on Becton Dickinson (BDX) to $208 from $204 and keeps a Buy rating on the shares. The firm is more optimistic on the medical…
Becton Dickinson price target raised to $190 from $180 at RBC Capital
RBC Capital raised the firm’s price target on Becton Dickinson (BDX) to $190 from $180 and keeps a Sector Perform rating on the shares. The company is building a growth…
BD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT Trial
Enrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgery FRANKLIN LAKES, N.J., Aug....
Becton Dickinson price target raised to $195 from $175 at Stifel
Stifel raised the firm’s price target on Becton Dickinson (BDX) to $195 from $175 and keeps a Buy rating on the shares.
Becton Dickinson price target raised to $180 from $175 at RBC Capital
RBC Capital analyst Shagun Singh raised the firm’s price target on Becton Dickinson (BDX) to $180 from $175 and keeps a Sector Perform rating on the shares. Becton Dickinson returned…
Becton Dickinson price target raised to $204 from $198 at Citi
Citi raised the firm’s price target on Becton Dickinson (BDX) to $204 from $198 and keeps a Buy rating on the shares.
Becton Dickinson price target raised to $210 from $190 at Jefferies
Jefferies raised the firm’s price target on Becton Dickinson (BDX) to $210 from $190 and keeps a Buy rating on the shares following a fiscal Q3 beat and guidance raise.
Becton, Dickinson and Company Earnings Call Transcript: Q3 2026
Q3 delivered strong revenue and EPS growth, driven by high-single- and double-digit gains across key platforms and robust operational execution. Updated guidance now anticipates revenue at the high end of the low-single-digit range and higher adjusted EPS, with continued momentum expected into 2027 despite defined headwinds from Alaris and stabilization in China and vaccines.
Becton, Dickinson and Company Slides: Q3 2026
Becton, Dickinson and Company has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 6, 2026.
Becton, Dickinson and Company Earnings release: Q3 2026
Becton, Dickinson and Company released its Q3 2026 earnings on August 6, 2026, summarizing the period's financial results.
Becton, Dickinson and Company Quarterly report: Q3 2026
Becton, Dickinson and Company has published its Q3 2026 quarterly earnings report on August 6, 2026.
BD Reports Third Quarter Fiscal 2026 Financial Results
Revenue of $5.0 billion increased 5.4% as reported, 4.4% FXN GAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.23, respectively Year-to-date cash from continuing operations incr...
Becton Dickinson price target raised to $182 from $163 at TD Cowen
TD Cowen raised the firm’s price target on Becton Dickinson (BDX) to $182 from $163 and keeps a Hold rating on the shares. The firm said they see a favorable…
FDA issues early alert about Becton Dickinson letter to remove device
The FDA is aware that Becton Dickinson (BDX) has issued a letter to affected customers recommending certain Intraosseous Vascular Access System Needle Sets be removed from where they are used…
Becton Dickinson issues recall on certain lots of needle sets used for emergency IV access
Becton Dickinson said on Friday it is issuing a recall on certain lots of medical needle sets in the U.S. after users reported difficulty in removing a part of the device after using it on patients.
Becton Dickinson recalls lots of Intraosseous Vascular Access System Needle Sets
Becton Dickinson (BDX) is voluntarily recalling specific lots of BD Intraosseous Vascular Access System Needle Sets to the user level. These products are being recalled following reports that some use...